Figure 2.

Biomarker excretion patterns surrounding cisplatin infusion at early and late cisplatin visits by serum creatinine-AKI status showing patients with AKI had higher urine biomarker levels. Graph shows box-and-whisker plots (the lower end of the boxes represents the 25th percentile, and the upper end of the boxes represents the 75th percentile; the middle line is the median; the upper whisker outlines the upper adjacent value, and the lower whisker outlines the lower adjacent value) of urine AKI biomarkers measured at three time points surrounding the cisplatin infusion at the early visit (left) and the late visit (right). Time points shown on the x axis: pre-infusion (Pre), before cisplatin infusion start on day of infusion (day 1); morning post-infusion (Post; day 2); and discharge, just before hospital discharge (day 2–5). The number of participants analyzed for each time point are indicated in boxes under each bar. Outliers were excluded. The Skillings–Mack test P value for comparing biomarker levels across the three time points within AKI or non-AKI groups are indicated in boxes at the top of each panel. No urine neutrophil gelatinase-associated lipocalin (NGAL) results were below the lower limit of detection. The number of urine kidney injury molecule-1 (KIM-1) values below the reportable range were as follows. For the early visit: pre, n=21; post, n=36; discharge, n=11. For the late visit: pre, n=8; post, n=29; discharge, n=9. (A) Urine NGAL at the early visit. (B) Urine NGAL at the late visit. (C) Urine KIM-1 at the early visit. (D) Urine KIM-1 at the late visit. *P<0.05, **P<0.01; indicates significant difference between AKI and non-AKI groups for that time point by Mann–Whitney U test. Creat, creatinine.